Georgiamune Inc.
Mark Avagliano currently serves as the Chief Business Officer at Georgiamune Inc., a position held since October 2024. Prior to this role, Avagliano was the Chief Business Officer at G1 Therapeutics, Inc. from July 2019 to September 2024. A significant portion of Avagliano's career was spent at Pfizer, where roles included Vice President of Corporate Development and various positions in Business Development from January 2007 to July 2019. Earlier experience includes working at Aventis Inc. as a Senior Analyst and Analyst from January 2000 to December 2004. Mark Avagliano holds a Master of Science in Finance and Accounting from The London School of Economics and Political Science and a Master of Science in Comparative Social Policy from the University of Oxford.
This person is not in any teams
This person is not in any offices
Georgiamune Inc.
Georgiamune Inc. is a private, science and discovery clinical stage immunotherapeutic biotechnology company focused on reprogramming immune signaling pathways to redirect the immune system to fight diseases. Unique approaches to re-establishing immune balance and groundbreaking scientific discoveries have led to the development of pioneering immune therapeutics for cancer and autoimmune diseases.